Journal of Diabetes Research

Journal of Diabetes Research / 2009 / Article

Research Article | Open Access

Volume 2009 |Article ID 910783 | 11 pages | https://doi.org/10.1155/2009/910783

Rosiglitazone Prevents High Glucose-Induced Vascular Endothelial Growth Factor and Collagen IV Expression in Cultured Mesangial Cells

Academic Editor: Mark Cooper
Received13 Aug 2008
Revised13 Dec 2008
Accepted27 Mar 2009
Published07 Jul 2009

Abstract

Peroxisome proliferator-activated receptor (PPAR ), a ligand-dependent transcription factor, negatively modulates high glucose effects. We postulated that rosiglitazone (RSG), an activator of PPAR prevents the upregulation of vascular endothelial growth factor (VEGF) and collagen IV by mesangial cells exposed to high glucose. Primary cultured rat mesangial cells were growth-arrested in 5.6 mM (NG) or 25 mM D-glucose (HG) for up to 48 hours. In HG, PPAR mRNA and protein were reduced within 3 h, and enhanced ROS generation, expression of , VEGF and collagen IV, and PKC- membrane association were prevented by RSG. In NG, inhibition of PPAR caused ROS generation and VEGF expression that were unchanged by RSG. Reduced AMP-activated protein kinase (AMPK) phosphorylation in HG was unchanged with RSG, and VEGF expression was unaffected by AMPK inhibition. Hence, PPAR is a negative modulator of HG-induced signaling that acts through PKC- but not AMPK and regulates VEGF and collagen IV expression by mesangial cells.

1. Introduction

The hallmark of progressive diabetic glomerulosclerosis is the accumulation of excessive extracellular matrix protein (ECM), mainly collagen IV, in the glomerular interstitium [1, 2]. This results in large part from the transformation of quiescent mesangial cells to a dedifferentiated myofibroblast phenotype as a result of the direct effects of high glucose and the response to autocrine and paracrine growth factors including vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)- [3, 4]. We and others have demonstrated that early mesangial cell responses to high glucose include the generation of reactive oxygen species (ROS) from NADPH oxidase, a necessary signaling factor in the stimulation of VEGF and collagen IV expression [3, 5].

Recent studies have suggested that peroxisome proliferator-activated receptor- (PPAR ) synthetic agonist thiazolidinediones, such as rosiglitazone, may prevent or attenuate diabetic nephropathy in animal models [6, 7]. PPAR is a member of the nuclear receptor superfamily of ligand-activated transcription factors. Upon ligand binding, PPAR forms a heterodimer with the retinoic X receptor. This complex then binds to PPAR response elements (PPREs) within the promoter region of target genes [8]. PPAR agonists have been shown to play an important role in regulating adipocyte differentiation, lipid and glucose metabolism, and inflammation [9]. Asano et al. [10] reported that rat mesangial cells express PPAR localized in the nucleus, and that troglitazone (an agonist of PPAR ) prevents cellular dedifferentiation as detected by reduced expression of -smooth muscle actin expression. PPAR agonists inhibit TGF- [11] and Ang II [12] stimulation of vascular smooth muscle cells, and mesangial cell proliferation and fibronectin synthesis in response to VEGF [13] and TGF- [14], respectively.

We have demonstrated that in response to high glucose, mesangial cells rapidly express and secrete VEGF that is dependent on the activation of both PKC- and PKC- , and the generation of reactive oxygen species (ROSs) [15]. Yang et al. reported [16] that hyperglycemic Zucker rats develop increased circulating VEGF and that the PPAR agonist pioglitazone normalized serum glucose and VEGF levels. Onozaki et al. [13] showed that during exposure to a rapid change in ambient glucose concentration, mesangial cell proliferation dependent on VEGF expression was inhibited by a thiazolidinedione. The cellular signaling mechanisms that connect the effects of high glucose to altered mesangial cell PPAR expression and function and consequent outcomes relevant to progressive glomerulosclerosis are unknown.

In this study, we postulated that rosiglitazone would reverse the effects of high glucose essential for the early responses of mesangial cells associated with myofibroblast transformation including ROS generation, VEGF and collagen IV expression. To identify the role of PPAR in mesangial cells, we tracked its expression and the effects of rosiglitazone during exposure to high glucose. The actions of rosiglitazone on high glucose-stimulated ROS generation via NADPH oxidase and the expression of VEGF and collagen IV were observed. These effects were confirmed by similar findings with two other PPAR agonists, Ciglitazone and Troglitazone. Supporting these observations, a specific inhibitor of PPAR , GW9662, on mesangial cell expression of VEGF in normal glucose and high glucose had opposite effects. To determine whether AMP-activated protein kinase (AMPK), reported to be activated by thiazolidinediones, is involved in this mesangial cell PPAR pathway, the phosphorylation of AMPK was analyzed in the presence of Compound C, a specific antagonist of AMPK [17], with and without rosiglitazone. Our data support a major role for downregulation of PPAR during the early response of mesangial cells to high glucose and reversal with rosiglitazone.

2. Materials and Methods

2.1. Materials

Dulbecco’s modified Eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from Invitrogen Corporation (Burlington, Ont, Canada). 5-(and-6)-chlormethyl- , -dichlorodihydrofluorescein diacetate (CM- DCFDA) was obtained from Molecular Probes Inc. (Eugene, Ore, USA). Rabbit Polyclonal antibodies against p2 and VEGF, and monoclonal antibodies against PPAR were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif, USA). Monoclonal antibody against -actin was purchased from Sigma-Aldrich (St, Louis, Mo, USA). Rabbit polyclonal antibody against type IV collagen was purchased from Rockland Immunochemicals (Gilbertsville, Pa, USA). The rabbit polyclonal antibodies against phospho- and total-AMPK alpha were purchased from Cell Signaling Technology, Inc. (Danvers, Mass, USA). The selective ATP-competitive inhibitor of AMPK, Compound C, and Ciglitazone were purchased from Calbiochem (Gibbstown, NJ, USA). Rosiglitazone and Troglitazone and GW9662 were purchased from Cayman Chemical (Ann Arbor, Mich, USA).

2.2. Cell Culture

Primary rat glomerular mesangial cells were isolated from Sprague-Dawley rat kidney cortex and cultured as previously described [18, 19]. The cells were cultured in DMEM containing 17% FBS, then routinely growth-arrested in 0.5% FBS for 48 hours in either normal D-glucose 5.6 mM or high D-glucose 25 mM, or 5.6 mM D-glucose + 24.4 mM L-glucose for up to 48 hours. In some experiments, cells were incubated with 10  M rosiglitazone, 10  M Ciglitazone, 10  M Troglitazone, and/or pretreated with 10  M GW9662 (a PPAR antagonist). AMPK activity was inhibited by pretreatment for 48 hours with 50 uM Compound C, a cell-permeable, selective ATP-competitive kinase inhibitor of AMPK [17, 20, 21]. The glitazone compounds were first dissolved in DMSO to create a 25.2 mmol/uL stock solution stored at − and then dissolved in DMEM to produce a final concentration of 10 uM in the cell culture medium.

2.3. Western Immunoblotting

Western immunoblots were performed with primary antibodies against PPAR p2 , VEGF, AMPK, -actin in total cell lysates, or PKC- , - in total cell lysates and cellular membrane fractions as we previously described [5, 15].

2.4. Quantitative Real-Time Polymerase Chain Reaction

Total cellular RNA was extracted from mesangial cells using an RNeasy kit (Qiagen, Valencia, Calif, USA). After the RNA was reverse transcribed, real-time PCR was performed with the following primers as described previously [15]. The primers for VEGF were (sense), -GATGAGATAGAGTATATCTTCAAGCCGT- , and (antisense), -TCTATCTTTCTTTGGTCTGCATTCAC- (GenBank: NM_031836). The primers for p2 were (sense), -TCCTCCACTTACTGCTGTCCGT- , and (antisense), -TCAATGGGAGTCCACTGCTCAC - (Genbank: MIM_131550).The primers for PPAR were (sense) -CCAGAGTCTGCTGATCTGCGA- , and (antisense), -GCCACCTCTTTGCTCTGCTC- (Genbank: MIM_131550). The primers for -actin were (sense) -AGGCCCCTCTGAACCCTAAG- , and (antisense), -CAACACAGCCTGGATGGCTAC- (Genbank: NM_031144).

2.5. Measurement of PPAR Promoter Activity

To assess PPAR function, mesangial cells were transiently transfected with a luciferase reporter gene containing three PPAR response elements and a thymidine kinase promoter [22] obtained from Addgene (Cambridge, Mass, USA). Cells were plated in 24 well plates and transfected with Fugen 6 (Roche, Indianapolis, Ind, USA) according to the manufacturer’s instructions. For measurement of luciferase activity, the transfected mesangial cells were growth-arrested in 0.5% FBS in 5.6 mM or 25 mM D-glucose for up to 48 hours. In some experiments, 10 uM rosiglitazone or/and 10  M GW9662 was added to the medium for 48 hours. The mesangial cells were then lysed on ice in a buffer containing glycylglycine 25 mM, pH 8, MgS 15 mM, EGTA 4 mM, 1% Triton X-100. Luciferase activity was detected in 50 uL of cell extract plus 100 uL of reaction buffer (glycylglycine 25 mM, pH 8, K P 15 mM, EGTA 4 mM, ATP 2 mM, MgS 15 mM, and CoA 0.1 mM) over 20 seconds in a plate reading luminometer. The results were normalized to total cell protein.

2.6. Confocal Imaging

To analyze collagen IV protein content, cells were cultured on glass coverslips and incubated with polyclonal antibody against collagen IV. The primary antibodies were detected using FITC-conjugated goat anti-rabbit IgG (Jackson Immunoresearch Laboratories, Inc; West Grove, Pa, USA). Immunofluorescence was observed by confocal imaging and fluorescence intensity per cell was analyzed as previously described [5, 15].

To analyze hydrogen peroxide content, mesangial cells were cultured on glass coverslips and incubated in the dark with 1  M of CM- DCFDA for 25 minutes at . Intracellular ROS production was detected by confocal laser scanning microscopy. Fluorescence intensity per cell was analyzed by Scion Image software (Scion Corporation, Frederick, Md, USA) as previously described [5, 15].

2.7. Statistical Analyses

All results are expressed as mean SEM. Statistical analyses were performed using Instat 2.01 (Graph Pad, Sacramento, Calif, USA). Unpaired Student tests were used to compare the means of two groups. One-way analysis of variance (ANOVA) was performed to compare the means of three groups or more, then the Tukey-Kramer multiple comparison test was applied for post test analysis. was considered to be statistically significant.

3. Results

3.1. Effects of High Glucose and Rosiglitazone on PPAR Expression

Mesangial cell expression of PPAR in high glucose was analyzed by incubating cells with 5.6 mM (normal glucose) or 25 mM (high glucose) D-glucose, or 5.6 mM D-glucose 24.4 mM L-glucose for up to 48 hours, with and without rosiglitazone. L-Glucose exposure for 48 hours had no effect on PPAR mRNA expression. Figure 1(a) shows that in high glucose, PPAR protein expression was reduced by 3 hours and sustained up to 48 hours as demonstrated by Western immunoblot. PPAR mRNA levels were significantly reduced by 24 hours continuing up to 48 hours Figure 1(b). We also demonstrated that neither rosiglitazone nor GW6992 (an antagonist of PPAR ), altered PPAR protein levels in high glucose [17, 23] Figure 1(c).

To investigate whether PPAR activation of transcription is reduced in high glucose and if rosiglitazone alters this response, mesangial cells were transiently transfected with a PPAR -luciferase reporter gene as described by others [24, 25]. Decreased luciferase activity was found at 1 to 48 hours of exposure to high glucose as shown in Figure 1(d). These data suggest that downregulation of PPAR expression in high glucose reduces the functional effect of PPAR on promoter activity. To determine whether rosiglitazone modulates PPAR stimulation of promoter activity, mesangial cells were pre-incubated with 1 to 20 uM rosiglitazone and promoter activity was measured. A maximum effect on luciferase activity was observed in normal glucose in the cells incubated with 5 uM rosiglitazone Figure 1(e), and in high glucose, 10 uM rosiglitazone stimulated luciferase to a similar maximum Figure 1(f). We then found that inhibition of PPAR receptor activity with GW6992 prevented the rosiglitazone-stimulated PPAR- responsive promoter activity both in normal glucose and high glucose Figure 1(f).

3.2. ROS Generation Regulated by PPAR

In high glucose, ROS generation appeared within 1 to 3 hours in DCF-loaded mesangial cells (Figure 2), as previously reported [5, 15]. We observed that 1 hour pretreatment with rosiglitazone abolished ROS generation during 3 to 48 hours of exposure to high glucose Figure 2(a). This effect of rosiglitazone was blocked by preincubation with GW9662 Figure 2(b). GW9662 alone caused generation of ROS in normal glucose.

We have reported that the NADPH oxidase subunit, p2 is upregulated in high glucose in mesangial cells [15]. To determine whether PPAR activation modifies high glucose-induced p2 expression, mesangial cells were exposed to 5.6 mM or 25 mM D-glucose for up to 48 hours. First, the cells were preincubated with 10  M rosiglitazone alone. As displayed in Figure 3(a), p2 protein levels in high glucose were increased as expected at 24 hours and 48 hours. Rosiglitazone not only prevented the effect of high glucose on p2 protein but also reduced the ambient level of this protein in normal glucose. Further, cells were tested with three different PPAR activators that all blocked high glucose-induced p2 protein expression as shown in Figure 3(b).

3.3. Rosiglitazone Prevents High Glucose-Induced VEGF and Collagen IV Expression in Mesangial Cells

To test the effect of PPAR activation and inhibition on VEGF expression, mesangial cells were growth-arrested and exposed to 5.6 mM or 25 mM D-glucose for up to 48 hours, with or without rosiglitazone or GW9662. The increase in VEGF mRNA levels was prevented by pretreatment with rosiglitazone Figure 4(a). Both Ciglitazone and Troglitazone also blocked high glucose-stimulated VEGF expression at 48 hours as detected by Western immunoblot Figure 4(b). Then, enhanced VEGF protein expression in high glucose was inhibited by pretreatment with 10 uM rosiglitazone at both 24 hours and 48 hours Figure 4(c) as detected by Western immunoblot. The inhibition of PPAR with GW9662 alone in normal glucose caused a significant increase in VEGF expression. Furthermore, this inhibitor reversed the effect of rosiglitazone on VEGF expression in mesangial cells in high glucose Figure 4(d).

To determine the effect of rosiglitazone on collagen IV expression, we first analyzed the effect of this PPAR activator on high glucose-induced mRNA expression. A significant increase in collagen IV mRNA was observed after 48 hours, but not 3 hours, in high glucose and this response was inhibited by rosiglitazone Figure 5(a). Intracellular collagen IV protein expression was assessed by immunofluorescence imaging. The increase in collagen IV protein at 3 and 24 hours was prevented by rosiglitazone pretreatment Figure 5(b).

3.4. Effect of Rosiglitazone on PKC- and - Membrane Translocation

Since our previous studies indicated a cause-and-effect relationship among the activation of PKC- and PKC- , ROS generation and both VEGF and collagen IV expression [5, 15], we wished to test whether rosiglitazone could affect these two key PKC isozymes that are relevant to the pathogenesis of diabetic glomerulophathy. As illustrated in Figure 6, in the presence of rosiglitazone, a reduction in membrane-association of PKC- , but not PKC- , was observed in both normal and high glucose. Total recoveries of both PKC isozymes in total cell lysate were unchanged in high glucose or in the presence of rosiglitazone.

3.5. Rosiglitazone and the AMPK Pathway

It has been reported that rosiglitazone reduces ROS production by NADPH oxidase independent of PPAR activity and that this effect may involve the AMPK pathway [17]. Thus, we determined whether inhibition of AMPK with Compound C would reverse the inhibition of ROS generation in response to HG observed during rosiglitazone treatment. Mesangial cells were growth-arrested and exposed to 5.6 mM or 25 mM D-glucose for up to 3 hours or 48 hours, with or without 1 hour pretreatment with 10  M rosiglitazone or 50  M Compound C, or both. In Figure 7, the effect of rosiglitazone on high glucose-induced ROS generation was reversed by coincubation with Compound C. Of note was that Compound C alone caused ROS generation in normal glucose at 48 hours. The enhanced generation of ROS by mesangial cells observed in high glucose at 3 and 48 hours was not affected by Compound C. However, in the presence of Compound C, the effect of rosiglitazone on ROS generation in high glucose was reversed in keeping with a possible AMPK-independent effect of Compound C on ROS generation.

The phosphorylation of AMPK in normal and high glucose at 3 hours was inhibited with Compound C as illustrated in Figure 8. In view of the generation of ROS during exposure to Compound C, these experiments were limited to 3 hours. VEGF protein expression in high glucose was also analyzed in the same protein samples. Rosiglitazone had no effect on AMPK phosphorylation in either normal or high glucose. While Compound C, as expected, inhibited AMPK phosphorylation in both normal and high glucose, it had no effect on VEGF expression in normal or high glucose. Furthermore, the inhibitory effect of rosiglitazone on enhanced VEGF expression at 3 hours in high glucose was not significantly affected by Compound C Figure 8(b).

4. Discussion

In this study, we identified that within the first 6 hours of exposure to high glucose, mesangial cell PPAR is downregulated and that rosiglitazone prevents the effects of high glucose on NADPH oxidase-dependent ROS generation, VEGF and collagen IV expression. The analysis of PPAR protein levels indicated a reduction as early as 3 hours following high glucose exposure, although significant reduction in PPAR mRNA levels was not detected until 6 hours, suggesting that high glucose may differentially alter translation and transcription. Differential regulation of PPAR protein and mRNA levels in high glucose could also be due to enhanced protein degradation following activation as demonstrated by Hauser et al. [26]. We demonstrated the dose response of the PPAR -stimulated promoter activity in response to increasing concentrations of rosiglitazone. Two other PPAR agonists, Ciglitazone and Troglitazone prevented high glucose-induced p2 and VEGF expression. Our data support the conclusion that rosiglitazone prevents the effects of high glucose on mesangial cell signaling and gene expression through PPAR .

We also found that rosiglitazone prevented high glucose-induced upregulation of NADPH oxidase subunit, p2 expression, correlating with the effect of rosiglitazone in attenuating ROS generation in response to high glucose. Further, an antagonist of the PPAR receptor, GW9662, caused ROS generation in normal glucose and prevented the effects of rosiglitazone. These data also support the conclusion that the effects of rosiglitazone in mesangial cells are likely mediated through PPAR . Our findings agree with those recently reported by Henderson et al. [27] and Tyagi et al. [28] who found that a PPAR agonist (Ciglitazone) prevented the ROS generation that was associated with an upregulation of the NADPH oxidase subunit (Nox4) in response to pressure overload and homocysteine in myocardium and in endothelial cells, respectively. The combination of PPAR and activators also inhibits angiotensin II-induced ROS production by NADPH oxidase in hypertensive rats [29]. Hwang et al. [30] recently reported that rosiglitazone reduces vascular oxidative stress and NADPH oxidase subunit expression in diabetic mice. We have shown that sustained production of ROS in mesangial cells in high glucose may be due to the upregulation of NADPH oxidase subunits, p4 and p2 via a PKC-dependent mechanism [5, 31]. The present study extends our findings to include a role for PPAR in the negative regulation of p2 expression in mesangial cells in the normal state as well as reversal of the increase induced by high glucose.

Recently, we published that in high glucose the upregulation of VEGF expression by mesangial cells is dependent on ROS generation by NADPH oxidase [15]. Evidence is increasing for an important functional relationship between PPAR and VEGF. Xin et al. [32] reported that the activation of PPAR with Ciglitazone in human umbilical vein endothelial cells reduced VEGF receptor 1 (Flt1) and 2 (Flk/KDR) expression. Further, Meissner et al. [33] demonstrated that PPAR activators inhibit VEGF receptor 2 expression via inhibition of Sp1-dependent DNA binding and trans-activation. In endothelial cells, PPAR activators inhibited VEGF-induced AKT phosphorylation and consequent endothelial cell migration [34]. Our present data are consistent with these reports and show that rosiglitazone abolished high glucose-stimulated VEGF expression in mesangial cells.

Our findings also illustrate that rosiglitazone prevented collagen IV expression by mesangial cells in high glucose. These results are in keeping with a number of studies relating PPAR activation to the prevention of extracellular matrix production relevant to kidney disease. Accelerated nephropathy is observed in diabetic PPAR -knockout mice due to collagen IV deposition [35]. The PPAR agonist fenofibrate prevents diabetic nephropathy in db/db mice [36]. In human kidney fibroblasts, the PPAR agonist, pioglitazone, reduces extracellular matrix production [37]. In mesangial cells, the PPAR agonist thiazolidinediones inhibit TGF- -induced fibronectin expression and ameliorate diabetic nephropathy [38, 39]. In renal tubular cells, pioglitazone activation of PPAR exerts antifibrotic effects in the setting of high glucose [40]. These findings do not exclude the possibility that PPAR activation in vivo may also prevent the accumulation of collagen IV through suppression of plasminogen activator inhibitor-1 [41].

To identify the mechanism(s) whereby PPAR regulates mesangial cell signaling and gene expression, we examined the effect of rosiglitazone on PKC- and - membrane-association patterns and on AMPK phosphorylation. The membrane-association of PKC- was inhibited by rosiglitazone, whereas PKC- was unaffected. We previously demonstrated the cause-and-effect relationship between the activation of mesangial cell PKC- in high glucose and subsequent generation of ROS, VEGF, and collagen IV expression in response to high glucose [5, 15]. Therefore, the observation that a PPAR activator appears to inhibit PKC- membrane association links PPAR to this specific PKC isozyme pathway. By contrast, rosiglitazone had no effect on AMPK phosphorylation, suggesting that PPAR in mesangial cells may not signal through this pathway. These results differ from a recent report in which rosiglitazone was observed to reduce glucose-induced oxidative stress mediated by NADPH oxidase via an AMPK-dependent mechanism in endothelial cells [17, 42]. In human neutrophils, AMPK activation inhibits ROS generation by NADPH oxidase [23]. We observed that in high glucose, mesangial cell AMPK phosphorylation was reduced. Taken together with the observation that inhibition of AMPK with Compound C was associated with ROS generation, it is possible that AMPK regulates ROS generation in mesangial cells, but separately from the action of PPAR . It appears that the signaling response of AMPK in high glucose may vary depending on the cell phenotype.

The precise mechanism whereby PPAR inhibits high glucose-stimulated VEGF, ROS formation, collagen IV expression, and PKC- is not known at present. A well-documented effect of PPAR is to inhibit TGF- expression and/or TGF- signaling giving rise to an antifibrotic effect, which can be demonstrated in vivo in models of lung fibrosis for example [38, 43]. Given that we have recently found that all of the above effects of high glucose depend on TGF- [44], inhibition of TGF- and its downstream signaling could account for the inhibitory effects of PPAR observed in the present study. Intriguingly, PPAR has been variably shown to prevent DNA binding, and in some cases to interact physically with different transcription factors, such as AP-1 [45], Sp1 [33, 46], nuclear factor-1 (NF-1) [47], NF- B [48]. Therefore, one could hypothesize that suppression of AP-1, Sp1, NF-1, or NF- B DNA binding could be sufficient to account for the effects of PPAR by reducing TGF- expression, interfering with the expression of proteins involved in TGF- signaling, and perhaps by directly affecting the expression of some of the above proteins, such as collagen IV, p2 , and VEGF.

In summary, mesangial cells demonstrate rapid downregulation of PPAR via both transcriptional and nontranscriptional regulation in response to high glucose. Treatment with rosiglitazone, linked to the PKC- pathway, attenuates high glucose-induced ROS generation and prevents VEGF and collagen IV expression through its action on PPAR . This study suggests that preventing the actions of high glucose on mesangial cell PPAR may be relevant in the treatment and prevention of diabetic glomerulopathy.

Acknowledgments

This work was supported by the Canadian Diabetes Association (C. Whiteside) and in part by grants from the Canadian Institutes of Health Research (CIHR) to I. G. Fantus (MOP 83025 and MOP 49409). L. Xia was a Post-doctoral fellow supported by the Canadian Diabetes Association and CIHR (MOP 49409).

References

  1. S. G. Adler, S. Feld, L. Striker et al., “Glomerular type IV collagen in patients with diabetic nephropathy with and without additional glomerular disease,” Kidney International, vol. 57, no. 5, pp. 2084–2092, 2000. View at: Publisher Site | Google Scholar
  2. R. M. Mason and N. A. Wahab, “Extracellular matrix metabolism in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 5, pp. 1358–1373, 2003. View at: Publisher Site | Google Scholar
  3. M. Haneda, D. Koya, M. Isono, and R. Kikkawa, “Overview of glucose signaling in mesangial cells in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 5, pp. 1374–1382, 2003. View at: Publisher Site | Google Scholar
  4. Y. Mao, T. Ootaka, T. Saito, H. Sato, T. Sato, and S. Ito, “The involvement of advanced glycation endproducts (AGEs) in renal injury of diabetic glomerulosclerosis: association with phenotypic change in renal cells and infiltration of immune cells,” Clinical and Experimental Nephrology, vol. 7, no. 3, pp. 201–209, 2003. View at: Publisher Site | Google Scholar
  5. L. Xia, H. Wang, S. Munk et al., “Reactive oxygen species, PKC-ß1, and PKC-? mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells,” American Journal of Physiology, vol. 293, no. 5, pp. E1280–E1288, 2007. View at: Publisher Site | Google Scholar
  6. A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas, “PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2399–2405, 2006. View at: Publisher Site | Google Scholar
  7. U. Panchapakesan, X. M. Chen, and C. A. Pollock, “Drug insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection,” Nature Clinical Practice Nephrology, vol. 1, no. 1, pp. 33–43, 2005. View at: Publisher Site | Google Scholar
  8. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at: Publisher Site | Google Scholar
  9. Y. Guan, Y. Zhang, and M. D. Breyer, “The role of PPARs in the transcriptional control of cellular processes,” Drug News and Perspectives, vol. 15, no. 3, pp. 147–154, 2002. View at: Publisher Site | Google Scholar
  10. T. Asano, M. Wakisaka, M. Yoshinari et al., “Peroxisome proliferator-activated receptor ?1 (PPAR?1) expresses in rat mesangial cells and PPAR? agonists modulate its differentiation,” Biochimica et Biophysica Acta, vol. 1497, no. 1, pp. 148–154, 2000. View at: Publisher Site | Google Scholar
  11. M. Fu, J. Zhang, Y. Lin et al., “Early stimulation and late inhibition of peroxisome proliferator-activated receptor ? (PPAR?) gene expression by transformino growth factor ß in human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads,” Biochemical Journal, vol. 370, no. 3, pp. 1019–1025, 2003. View at: Publisher Site | Google Scholar
  12. S. Wakino, K. Hayashi, T. Kanda et al., “Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2,” Circulation Research, vol. 95, no. 5, pp. e45–e55, 2004. View at: Publisher Site | Google Scholar
  13. A. Onozaki, S. Midorikawa, H. Sanada et al., “Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione,” Biochemical and Biophysical Research Communications, vol. 317, no. 1, pp. 24–29, 2004. View at: Publisher Site | Google Scholar
  14. A. Maeda, S. Horikoshi, T. Gohda, T. Tsuge, K. Maeda, and Y. Tomino, “Pioglitazone attenuates TGF-β1-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)γ,” Cell Biology International, vol. 29, no. 6, pp. 422–428, 2005. View at: Publisher Site | Google Scholar
  15. L. Xia, H. Wang, H. J. Goldberg, S. Munk, I. G. Fantus, and C. I. Whiteside, “Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression,” American Journal of Physiology, vol. 290, no. 2, pp. F345–F356, 2006. View at: Publisher Site | Google Scholar
  16. B. Yang, P. Lin, K. M. Carrick et al., “PPAR? agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats,” Biochemical and Biophysical Research Communications, vol. 334, no. 1, pp. 176–182, 2005. View at: Publisher Site | Google Scholar
  17. G. Ceolotto, A. Gallo, I. Papparella et al., “Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2627–2633, 2007. View at: Publisher Site | Google Scholar
  18. J. A. Dlugosz, S. Munk, J. Kapor-Drezgic et al., “Stretch-induced mesangial cell ERK1/ERK2 activation is enhanced in high glucose by decreased dephosphorylation,” American Journal of Physiology, vol. 279, no. 4, pp. F688–F697, 2000. View at: Google Scholar
  19. J. Kapor-Drezgic, X. Zhou, T. Babazono, J. A. Dlugosz, T. Hohman, and C. I. Whiteside, “Effect of high glucose on mesangial cell protein kinase and C-δ and -ε is polyol pathway-dependent,” Journal of the American Society of Nephrology, vol. 10, no. 6, pp. 1193–1203, 1999. View at: Google Scholar
  20. J. Pandhare, S. K. Cooper, and J. M. Phang, “Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor γ-dependent and -independent mechanisms,” The Journal of Biological Chemistry, vol. 281, no. 4, pp. 2044–2052, 2006. View at: Publisher Site | Google Scholar
  21. J.-M. Ye, N. Dzamko, A. J. Hoy, M. A. Iglesias, B. Kemp, and E. Kraegen, “Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats,” Diabetes, vol. 55, no. 10, pp. 2797–2804, 2006. View at: Publisher Site | Google Scholar
  22. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at: Publisher Site | Google Scholar
  23. G. Alba, R. El Bekay, M. Álvarez-Maqueda et al., “Stimulators of AMP-activated protein kinase inhibit the respiratory burst in human neutrophils,” FEBS Letters, vol. 573, no. 1–3, pp. 219–225, 2004. View at: Publisher Site | Google Scholar
  24. A. Aiello, G. Pandini, F. Frasca et al., “Peroxisomal proliferator-activated receptor-? agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells,” Endocrinology, vol. 147, no. 9, pp. 4463–4475, 2006. View at: Publisher Site | Google Scholar
  25. F. Turturro, R. Oliver III, E. Friday, I. Nissim, and T. Welbourne, “Troglitazone and pioglitazone interactions via PPAR-γ-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines,” American Journal of Physiology, vol. 292, no. 3, pp. C1137–C1146, 2007. View at: Publisher Site | Google Scholar
  26. S. Hauser, G. Adelmant, P. Sarraf, H. M. Wright, E. Mueller, and B. M. Spiegelman, “Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation,” The Journal of Biological Chemistry, vol. 275, no. 24, pp. 18527–18533, 2000. View at: Publisher Site | Google Scholar
  27. B. C. Henderson, U. Sen, C. Reynolds et al., “Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone,” International Journal of Biological Sciences, vol. 3, no. 6, pp. 385–392, 2007. View at: Google Scholar
  28. N. Tyagi, K. S. Moshal, U. Sen, D. Lominadze, A. V. Ovechkin, and S. C. Tyagi, “Ciglitazone ameliorates homocysteine-mediated mitochondrial translocation and matrix metalloproteinase-9 activation in endothelial cells by inducing peroxisome proliferator activated receptor-γ activity,” Cellular and Molecular Biology, vol. 52, no. 5, pp. 21–27, 2006. View at: Google Scholar
  29. C. De Ciuceis, F. Amiri, M. Iglarz, J. S. Cohn, R. M. Touyz, and E. L. Schiffrin, “Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats,” British Journal of Pharmacology, vol. 151, no. 1, pp. 45–53, 2007. View at: Publisher Site | Google Scholar
  30. J. Hwang, D. J. Kleinhenz, H. L. Rupnow et al., “The PPAR? ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice,” Vascular Pharmacology, vol. 46, no. 6, pp. 456–462, 2007. View at: Publisher Site | Google Scholar
  31. A. Fontayne, P. M. Dang, M. A. Gougerot-Pocidalo, and J. El-Benna, “Phosphorylation of p47phox sites by PKC α, βII, δ, and ζ: effect on binding to p22phox and on NADPH oxidase activation,” Biochemistry, vol. 41, no. 24, pp. 7743–7750, 2002. View at: Publisher Site | Google Scholar
  32. X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo,” The Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999. View at: Publisher Site | Google Scholar
  33. M. Meissner, M. Stein, C. Urbich et al., “PPARa activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation,” Circulation Research, vol. 94, no. 3, pp. 324–332, 2004. View at: Publisher Site | Google Scholar
  34. S. Goetze, F. Eilers, A. Bungenstock et al., “PPAR activators inhibit endothelial cell migration by targeting Akt,” Biochemical and Biophysical Research Communications, vol. 293, no. 5, pp. 1431–1437, 2002. View at: Publisher Site | Google Scholar
  35. C. W. Park, H. W. Kim, S. H. Ko et al., “Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor a,” Diabetes, vol. 55, no. 4, pp. 885–893, 2006. View at: Publisher Site | Google Scholar
  36. C. W. Park, Y. Zhang, X. Zhang et al., “PPARa agonist fenofibrate improves diabetic nephropathy in db/db mic,” Kidney International, vol. 69, no. 9, pp. 1511–1517, 2006. View at: Publisher Site | Google Scholar
  37. S. Zafiriou, S. R. Stanners, S. Saad, T. S. Polhill, P. Poronnik, and C. A. Pollock, “Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 638–645, 2005. View at: Publisher Site | Google Scholar
  38. B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda, “Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells,” Diabetes, vol. 53, no. 1, pp. 200–208, 2004. View at: Publisher Site | Google Scholar
  39. T. Okada, J. Wada, K. Hida et al., “Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms,” Diabetes, vol. 55, no. 6, pp. 1666–1677, 2006. View at: Publisher Site | Google Scholar
  40. U. Panchapakesan, S. Sumual, C. A. Pollock, and X. Chen, “PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose,” American Journal of Physiology, vol. 289, no. 5, pp. F1153–F1158, 2005. View at: Publisher Site | Google Scholar
  41. X. Yu, C. Li, X. Li, and L. Cai, “Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1,” Toxicological Sciences, vol. 96, no. 2, pp. 346–356, 2007. View at: Publisher Site | Google Scholar
  42. M.-H. Zou and Y. Wu, “AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 5-6, pp. 535–545, 2008. View at: Publisher Site | Google Scholar
  43. J. E. Milam, V. G. Keshamouni, S. H. Phan et al., “PPAR-? agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis,” American Journal of Physiology, vol. 294, no. 5, pp. L891–L901, 2008. View at: Publisher Site | Google Scholar
  44. L. Xia, H. Wang, S. Munk et al., “High glucose activates PKC-? and NADPH oxidase through autocrine TGF-ß1 signaling in mesangial cells,” American Journal of Physiology, vol. 295, no. 6, pp. F1705–F1714, 2008. View at: Publisher Site | Google Scholar
  45. S. Hazra, S. Xiong, J. Wang et al., “Peroxisome proliferator-activated receptor ? induces a phenotypic switch from activated to quiescent hepatic stellate cells,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 11392–11401, 2004. View at: Publisher Site | Google Scholar
  46. A. Sugawara, A. Uruno, M. Kudo et al., “Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-? via an interaction with Sp1 in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 277, no. 12, pp. 9676–9683, 2002. View at: Publisher Site | Google Scholar
  47. S. Yavrom, L. Chen, S. Xiong, J. Wang, R. A. Rippe, and H. Tsukamoto, “Peroxisome proliferator-activated receptor γ suppresses proximal α1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells,” The Journal of Biological Chemistry, vol. 280, no. 49, pp. 40650–40659, 2005. View at: Publisher Site | Google Scholar
  48. S. Ohga, K. Shikata, K. Yozai et al., “Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-?B activation,” American Journal of Physiology, vol. 292, no. 4, pp. F1141–F1150, 2007. View at: Publisher Site | Google Scholar

Copyright © 2009 Catharine Whiteside et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

953 Views | 625 Downloads | 19 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.